By Mill Chart
Last update: Apr 17, 2024
Our stock screener has singled out GILEAD SCIENCES INC (NASDAQ:GILD) as a promising choice for dividend investors. NASDAQ:GILD not only scores well in profitability, solvency, and liquidity but also offers a decent dividend. We'll explore this further.
ChartMill provides a Dividend Rating for every stock, ranging from 0 to 10. This rating assesses various dividend aspects, including yield, growth, and sustainability. NASDAQ:GILD earns a 7 out of 10:
To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:GILD has earned a 5 out of 10:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:GILD, the assigned 7 is a significant indicator of profitability:
Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.
Our latest full fundamental report of GILD contains the most current fundamental analsysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
GILEAD SCIENCES INC
NASDAQ:GILD (4/29/2024, 11:00:09 AM)
66.58
+1.16 (+1.77%)
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Despite an arsenal of drugs, many Americans are still unaware of their infections until it’s too late. A Biden initiative languishes without Congressional approval.
Explore these three dividend stocks trading near their 52-week lows, presenting compelling opportunities for income-oriented investors.
GILD earnings call for the period ending March 31, 2024.
GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gilead Sciences (NASDAQ:GILD) just reported results for the first quarter of 20...
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top S&P500 gainers and losers in today's after hours session.
Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury.